Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

201.74 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	470
Open	201.74
Bid (Size)	194.93 (100)
Ask (Size)	204.01 (200)
Prev. Close	201.74
Today's Range	201.74 - 201.74
52wk Range	44.05 - 224.31
Shares Outstanding	106,313,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? ↗

September 24, 2026

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

Via The Motley Fool

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.

Via The Motley Fool

Performance

YTD	+155.3%	+155.3%
1 Month	-1.9%	-1.9%
3 Month	+4.7%	+4.7%
6 Month	+117.6%	+117.6%
1 Year	+337.9%	+337.9%

More News

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? ↗

September 17, 2026

Via The Motley Fool

Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗

August 05, 2026

Via Chartmill

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗

July 30, 2026

Via Chartmill

MarketBeat Week in Review – 09/07 - 09/11 ↗

September 12, 2026

Via MarketBeat

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Via The Motley Fool

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

Via MarketBeat

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today ↗

September 04, 2026

Via Benzinga

Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer ↗

August 28, 2026

Via MarketBeat

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? ↗

August 28, 2026

Via The Motley Fool

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today ↗

August 26, 2026

Via Benzinga

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? ↗

August 25, 2026

Via The Motley Fool

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Via The Motley Fool

Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗

August 18, 2026

Via The Motley Fool

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗

August 07, 2026

Via Benzinga

Revolution Medicines Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗

August 03, 2026

Via The Motley Fool

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗

August 02, 2026

Via The Motley Fool

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

Via The Motley Fool

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗

July 17, 2026

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

Via The Motley Fool

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

July 07, 2026

From Revolution Medicines, Inc.

Via GlobeNewswire

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

Via The Motley Fool

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?

Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.

What exchange does Revolution Medicines, Inc. - Common Stock trade on?

Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?

The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market

What is the current price of Revolution Medicines, Inc. - Common Stock?

The current price of Revolution Medicines, Inc. - Common Stock is 201.74

When was Revolution Medicines, Inc. - Common Stock last traded?

The last trade of Revolution Medicines, Inc. - Common Stock was at 09/28/26 04:00 PM ET

What is the market capitalization of Revolution Medicines, Inc. - Common Stock?

The market capitalization of Revolution Medicines, Inc. - Common Stock is 21.45B

How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?

Revolution Medicines, Inc. - Common Stock has 21B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.